PE20160591A1 - Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma) - Google Patents

Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)

Info

Publication number
PE20160591A1
PE20160591A1 PE2016000615A PE2016000615A PE20160591A1 PE 20160591 A1 PE20160591 A1 PE 20160591A1 PE 2016000615 A PE2016000615 A PE 2016000615A PE 2016000615 A PE2016000615 A PE 2016000615A PE 20160591 A1 PE20160591 A1 PE 20160591A1
Authority
PE
Peru
Prior art keywords
aml
myeloid leukemia
acute myeloid
combination treatment
new combination
Prior art date
Application number
PE2016000615A
Other languages
English (en)
Inventor
Brian Higgins
Kathryn E Packman
Gwen Nichols
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160591A1 publication Critical patent/PE20160591A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invencion se refiere a un producto farmaceutico que comprende: a) como primer componente un inhibidor de la interaccion MDM2-p53, y b) como segundo componente, citarabina, como preparacion combinada para la utilizacion secuencial o simultanea en el tratamiento del cancer, particularmente de la LMA.
PE2016000615A 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma) PE20160591A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05

Publications (1)

Publication Number Publication Date
PE20160591A1 true PE20160591A1 (es) 2016-06-11

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000615A PE20160591A1 (es) 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)

Country Status (31)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HK (1) HK1222808A1 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI678204B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
PE20160591A1 (es) * 2013-12-05 2016-06-11 Hoffmann La Roche Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
CN108348571B (zh) * 2015-09-03 2022-03-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
EP3463358A4 (en) * 2016-06-06 2020-07-22 Celgene Corporation TREATMENT OF HEMATOLOGICAL MALIGNANT TUMOR WITH 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2- DIFLUOROACETAMIDE
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
MX2019005623A (es) 2016-11-15 2019-08-14 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.
JP6617208B2 (ja) * 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
AU2020323033A1 (en) * 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
WO2022241036A1 (en) * 2021-05-13 2022-11-17 Nkarta, Inc. Dosing regimens for cancer immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003241326B2 (en) * 2002-05-02 2008-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
CA2800519A1 (en) * 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
PE20160591A1 (es) * 2013-12-05 2016-06-11 Hoffmann La Roche Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
HK1222808A1 (zh) 2017-07-14
MX2016007170A (es) 2016-09-08
PT3077004T (pt) 2020-04-16
EP3077004B1 (en) 2020-02-19
JP2018111700A (ja) 2018-07-19
AR098576A1 (es) 2016-06-01
PL3077004T3 (pl) 2020-08-10
IL244888A0 (en) 2016-05-31
BR112016009669B1 (pt) 2023-01-24
CL2016001345A1 (es) 2017-04-07
US20220031726A1 (en) 2022-02-03
MX370618B (es) 2019-12-17
CR20160173A (es) 2016-06-08
JP2016539160A (ja) 2016-12-15
CA2926307A1 (en) 2015-06-11
JP6918724B2 (ja) 2021-08-11
JP6297695B2 (ja) 2018-03-20
KR20160070190A (ko) 2016-06-17
TW201526890A (zh) 2015-07-16
US20200253999A1 (en) 2020-08-13
AU2014359422B2 (en) 2020-03-05
SI3077004T1 (sl) 2020-07-31
PH12016500933A1 (en) 2016-06-27
DK3077004T3 (da) 2020-04-27
TWI627954B (zh) 2018-07-01
RS60142B1 (sr) 2020-05-29
US20160303158A1 (en) 2016-10-20
EP3077004A1 (en) 2016-10-12
EA201690785A1 (ru) 2016-10-31
AU2014359422A1 (en) 2016-04-28
US9956243B2 (en) 2018-05-01
SG11201604504VA (en) 2016-07-28
BR112016009669A8 (pt) 2020-04-07
ES2785203T3 (es) 2020-10-06
CN105792847A (zh) 2016-07-20
CA2926307C (en) 2021-11-16
KR101862955B1 (ko) 2018-05-31
JP2021091690A (ja) 2021-06-17
MA39040A1 (fr) 2018-01-31
CN105792847B (zh) 2019-11-08
IL244888B (en) 2020-11-30
US20230381215A1 (en) 2023-11-30
TW201840310A (zh) 2018-11-16
WO2015082384A1 (en) 2015-06-11
HRP20200566T1 (hr) 2020-06-26
HUE049434T2 (hu) 2020-09-28
ZA201602829B (en) 2017-04-26
US20150157603A1 (en) 2015-06-11
TWI678204B (zh) 2019-12-01
LT3077004T (lt) 2020-05-11

Similar Documents

Publication Publication Date Title
PE20160591A1 (es) Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
UY36075A (es) Derivados de tubulisina
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
CO2017002472A2 (es) Formulación de acetato de abiraterona
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CO2017000552A2 (es) Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70
MY179576A (en) Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
BR112016002311A2 (pt) combinações de inibidor de cinase de pim

Legal Events

Date Code Title Description
FA Abandonment or withdrawal